Clinical trials
Low Risk Prostate Cancer clinical trials
Below are recruiting low risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 163 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT06200974Recruiting
Genetic study of HDR brachytherapy for low-risk prostate cancer
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
Kelowna, British ColumbiaAges 18 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT06117059Recruiting
Precision study: 3 session prostate radiation with special guidance
This trial tests a new way to give prostate radiation using just 3 sessions with a special guidance system (RayPilot HypoCath) to target the tumor more accurately and safely.
EdinburghAges Any age - NCT06062745RecruitingPhase 1
PET scan study for prostate cancer with low PSMA or neuroendocrine features
This study tests a special PET scan (fluciclovine) to see if it can better detect prostate cancer that has low PSMA levels or has changed to a neuroendocrine type. It may help find tumors that standard PSMA scans miss.
Boston, MassachusettsAges 18 years+ - NCT06052683Recruiting
Comparing radiation side effects for low-risk prostate cancer
This trial compares two types of radiation therapy (SBRT and LDR brachytherapy) for men with low-risk or favorable intermediate-risk prostate cancer. The goal is to see which treatment causes fewer side effects.
Québec, QuebecAges 18 years+ - NCT05948657Recruiting
PSMA PET-CT scan for men on prostate cancer surveillance
This study checks whether a special prostate scan called PSMA PET-CT (along with standard monitoring scans) can help guide care while you are on “active surveillance” instead of immediate treatment. It may help doctors track low-risk prostate cancer changes more accurately over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+ - NCT05804318Recruiting
Adaptive daily radiation for low- and intermediate-risk prostate cancer
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
Duarte, CaliforniaAges 18 years+ - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
West Los Angeles, CaliforniaAges 18 years+ - NCT05590624Recruiting
Mediterranean diet study for men on prostate cancer active surveillance
This trial studies how different controlled versions of a Mediterranean-style diet may affect prostate cancer-related metabolism in men choosing active surveillance. It may help participants understand whether diet changes influence markers linked to prostate cancer activity, while keeping them on a monitored care plan.
Cleveland, OhioAges 18 years+ - NCT05586360RecruitingPhase 2
Testing how a statin may change immune markers in prostate cancer
This Phase 2 study tests whether taking simvastatin can change “immune regulation” markers in men with intermediate- to high-risk localized prostate cancer. It also looks at whether this could help lower the risk of cancer coming back after planned prostate surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05463796Recruiting
Prevention and early detection for people at high cancer risk
This study looks at surveillance (watching closely), prevention, and early “interception” steps to lower the chance that cancer will develop or be found later. It is for people with genetic risk, past cancer treatment exposures, strong family history, or certain early pre-cancer or high-risk conditions.
Boston, MassachusettsAges Any age - NCT05438563Recruiting
MRI-guided prostate cancer ablation with ultrasound from the urethra
This trial tests a newer way to treat certain low- to intermediate-risk prostate cancers using MRI guidance and an ultrasound probe placed through the urethra. It aims to destroy the tumor while using imaging to help target it more precisely.
Rochester, MinnesotaAges 45–80 - NCT05448547RecruitingPhase 3
Tested curative vs conservative treatment for older men with high-risk prostate cancer
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
CopenhagenAges 75 years+ - NCT05361798RecruitingPhase 2
Testing immune response after prostate radiation with or without a drug
This study checks how your immune system’s cancer-fighting cells change after stereotactic body radiation (SBRT) to the prostate. It compares SBRT alone versus SBRT plus an immunotherapy drug (PDS01ADC) in men with intermediate- or high-risk localized prostate cancer treated with hormone therapy (ADT).
Bethesda, MarylandAges 18 years+ - NCT05346848RecruitingPhase 2
Darolutamide plus radiation for intermediate-risk prostate cancer
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
AvignonAges 18 years+ - NCT05313191Recruiting
Proton therapy for tumors after prior radiation
This study looks at whether a type of proton beam treatment can be given safely and effectively to tumors that have already been treated with radiation before. It may help people whose tumors came back or persisted after earlier radiation, using a specific proton method called pencil beam scanning.
New York, New YorkAges 18 years+ - NCT03933670RecruitingPhase 2
MRI scan with special sugar to monitor prostate cancer on surveillance
This study uses a special MRI scan using “hyperpolarized” labeled pyruvate (a sugar-like substance) to see how prostate cancer may be behaving in people who are on active surveillance. It may help researchers monitor cancer without immediate treatment, by spotting changes earlier.
San Francisco, CaliforniaAges 18 years+ - NCT03769766RecruitingPhase 3
Curcumin to help keep low-risk prostate cancer from worsening
This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.
Dallas, TexasAges 40–89 - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03650595Recruiting
MRI-guided laser treatment for prostate cancer
This trial tests a minimally invasive prostate treatment using MRI guidance and a focal laser to destroy only the cancer spot (not the whole prostate). If you have low-to-intermediate risk, MRI-visible prostate cancer in a limited area, it may help control the cancer while potentially reducing treatment side effects.
Toronto, OntarioAges 40–80 - NCT02759744Enrolling by invitation
Laser treatment for certain prostate tumors guided by MRI images
This trial tests whether a precisely targeted laser procedure—guided by MRI images—can treat prostate cancer. It may help some men who have a certain type and location of tumor while aiming to avoid nearby sensitive structures.
Bethesda, MarylandAges 18–100 - NCT01492972RecruitingPhase 3
Lighter radiation, with or without hormone suppression
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Scottsdale, ArizonaAges 18 years+
Hear when a new Low Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low risk prostate cancer?
- Yes. Clin2 currently lists 163 recruiting low risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.